Patents by Inventor Runyan LI

Runyan LI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE FORMS OF BIARYL YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS
    Publication number: 20250011307
    Abstract: The present invention generally relates to crystalline polymorphic forms of the biaryl YAP/TAZ-TEAD protein-protein interaction inhibitors 4-((2S,4S)-5-Chloro-6-fluoro-2-phenyl-2-((S)-pyrrolidin-2-yl)-2,3-dihydrobenzofuran-4-yl)-5-fluoro-6-(2-hydroxyethoxy)-N-methylnicotinamide and 2-((2S,3S,4S)-5-Chloro-6-fluoro-3-methyl-2-((methylamino)methyl)-2-phenyl-2,3-dihydrobenzofuran-4-yl)-3-fluoro-4-methoxybenzamide and salts thereof, as well as methods of using the forms in the treatment of cancer.
    Type: Application
    Filed: August 30, 2022
    Publication date: January 9, 2025
    Inventors: Runyan LI, Bo LIU, Michael MUTZ, Lina YUAN, Yingcong ZHOU
  • COMPOSITIONS AND DOSAGE FORMS FOR TREATMENT OF HPV INFECTION AND HPV-INDUCED NEOPLASIA
    Publication number: 20240150381
    Abstract: A pharmaceutically acceptable salt of an acyclic nucleotide phosphoramidate to treat HPV and related conditions including neoplasia, as well as pharmaceutical compositions, morphic forms and dosage forms thereof.
    Type: Application
    Filed: October 31, 2023
    Publication date: May 9, 2024
    Applicant: Antiva Biosciences, Inc.
    Inventors: Barry Aldous, Ramakrishna Gadiraju, Sarah Walter, Oranee Daniels, Gail Maderis, Ankush Argade, Ravichandran Mahalingam, Zhengle Zhao, Zhaoyang Qin, Siyi Jiang, Runyan Li
  • TREATMENT OF HPV-INDUCED NEOPLASIA
    Publication number: 20240139221
    Abstract: A pharmaceutically acceptable salt of an acyclic nucleotide phosphoramidate to treat HPV and related conditions including neoplasia, as well as pharmaceutical compositions, morphic forms and dosage forms thereof.
    Type: Application
    Filed: October 31, 2023
    Publication date: May 2, 2024
    Applicant: Antiva Biosciences, Inc
    Inventors: Barry Aldous, Ramakrishna Gadiraju, Sarah Walter, Oranee Daniels, Gail Maderis, Ankush Argade, Ravichandran Mahalingam, Zhengle Zhao, Zhaoyang Qin, Siyi Jiang, Runyan Li
  • TREATMENT OF HPV INFECTION
    Publication number: 20240139220
    Abstract: A pharmaceutically acceptable salt of an acyclic nucleotide phosphoramidate to treat HPV and related conditions including neoplasia, as well as pharmaceutical compositions, morphic forms and dosage forms thereof.
    Type: Application
    Filed: October 31, 2023
    Publication date: May 2, 2024
    Applicant: Antiva Biosciences, Inc.
    Inventors: Barry Aldous, Ramakrishna Gadiraju, Sarah Walter, Oranee Daniels, Gail Maderis, Ankush Argade, Ravichandran Mahalingam, Zhengle Zhao, Zhaoyang Qin, Siyi Jiang, Runyan Li
  • COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS
    Publication number: 20210253534
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Application
    Filed: April 21, 2021
    Publication date: August 19, 2021
    Inventors: Donatella CHIANELLI, Runyan LI, Valentina MOLTENI, John NELSON, Jason Thomas ROLAND, Paul Vincent RUCKER, David Charles TULLY, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Yubo ZHANG, Bo ZHOU
  • Compositions and methods for modulating farnesoid X receptors
    Patent number: 11021446
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: June 1, 2021
    Assignee: Novartis AG
    Inventors: Donatella Chianelli, Runyan Li, Valentina Molteni, John Nelson, Jason Thomas Roland, Paul Vincent Rucker, David Charles Tully, Xiaoyang Wang, Liladhar Murlidhar Waykole, Yubo Zhang, Bo Zhou
  • COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS
    Publication number: 20200247757
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Application
    Filed: April 21, 2020
    Publication date: August 6, 2020
    Inventors: Donatella CHIANELLI, Runyan LI, Valentina MOLTENI, John NELSON, Jason Thomas ROLAND, Paul Vincent RUCKER, David Charles TULLY, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Yubo ZHANG, Bo ZHOU
  • COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS
    Publication number: 20190062283
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Application
    Filed: August 7, 2018
    Publication date: February 28, 2019
    Inventors: Donatella CHIANELLI, Runyan LI, Valentina Molteni, John Nelson, Jason Thomas Roland, Paul Vincent Rucker, David Charles Tully, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Yubo ZHANG, Bo ZHOU